Company Insights

ADIL supplier relationships

Explore interactive graphBrowse insights index
ADIL supplier relationship map

ADIL supplier map and what it means for investors

Adial Pharmaceuticals operates as a clinical-stage biopharmaceutical developer focused on AD04, a candidate for addictions and related disorders. The company monetizes by advancing AD04 through clinical development toward regulatory approval, licensing intellectual property from the University of Virginia, and preparing manufacturing and commercialization pathways via third‑party partners and capital markets transactions. Revenue is currently zero and value is driven by clinical progress, intellectual property exclusivity, and the robustness of supplier and commercialization arrangements. For a compact supply- and partner-focused intelligence offering, visit https://nullexposure.com/.

Who Adial is contracting with today — the partner roll call

The following summarizes every counterpart referenced in public filings and press releases found in the results set. Each relationship is described in plain English with the source called out.

  • Cambrex
    Adial has secured a manufacturing agreement with Cambrex to support drug substance or drug product supply for AD04 in clinical development and potential post‑approval commercialization. According to Adial’s March 6, 2026 business update on GlobeNewswire, Cambrex is named as a U.S. manufacturing partner. (GlobeNewswire, March 6, 2026.)

  • Thermo Fisher Scientific (TMO)
    Thermo Fisher is contracted as a U.S. manufacturing partner to help produce AD04 for late‑stage trials and commercialization readiness. Adial listed Thermo Fisher among its secured U.S. manufacturing supply partnerships in both its SEC filing summary and press releases. (Adial 8‑K / StockTitan and GlobeNewswire, March 2026.)

  • Cytel Inc.
    Adial engaged Cytel to provide advanced clinical trial design and statistical methodology support as it plans AD04 Phase 3 activities. The engagement was disclosed in the company’s March 6, 2026 business update. (GlobeNewswire, March 6, 2026.)

  • Genomind
    Adial partnered with Genomind to implement precision‑medicine testing and genotype‑guided therapeutic strategies that will support AD04 clinical development and patient selection efforts. This collaboration is reported in the March 2026 company update. (GlobeNewswire, March 6, 2026.)

  • VStock Transfer, LLC
    VStock Transfer is acting as Adial’s transfer agent and paying agent for a reverse stock split and related stockholder exchange process; the company provided instructions to shareholders regarding certificate exchange. This role is documented in the reverse split announcement. (GlobeNewswire and SahmCapital reporting, February 3–4, 2026.)

  • A.G.P./Alliance Global Partners
    A.G.P. served as Adial’s exclusive financial advisor for a warrant inducement transaction intended to raise approximately $2.86 million in gross proceeds. The advisory role is disclosed in Adial’s November 26, 2025 warrant inducement press release. (GlobeNewswire, November 26, 2025.)

  • Nasdaq (NDAQ)
    Nasdaq functions as the listing exchange for Adial’s common stock; corporate filings note that Adial’s common shares continued to trade on the Nasdaq Capital Market and were adjusted for a reverse stock split effective February 6, 2026. (Adial press release on Nasdaq listing details, February 3, 2026.)

  • Crescendo Communications, LLC
    Crescendo Communications is listed repeatedly as Adial’s investor relations/communications contact and is the named PR/IR firm on multiple company press releases. The firm handles investor communications and press distribution for corporate announcements. (Various Adial press releases, Jan–Mar 2026.)

If you want an investor‑grade partner map and supplier scoring model for ADIL, see the service at https://nullexposure.com/.

How these relationships define Adial’s operating model

Adial’s contract profile and supplier posture create a clear operating pattern:

  • Contracting posture: primarily outsourced and partnership‑driven. Adial relies on external manufacturers (Cambrex, Thermo Fisher), clinical design partners (Cytel), and precision testing vendors (Genomind) instead of owning large internal GMP or clinical analytics capacity. That lowers fixed costs but increases dependency on suppliers’ compliance and delivery timelines.
  • Concentration and criticality: supplier relationships are strategically critical but not excessively concentrated on a single vendor. The naming of two major U.S. manufacturers reduces sole‑source risk for production, but the overall supplier ecosystem remains critical because Adial lacks in‑house manufacturing scale.
  • Contract maturity and term structure: mixed short‑term and framework agreements. Corporate disclosures show a mix of licensing (long‑dated intellectual property arrangements with the University of Virginia) and short‑term or project contracts (consulting and shared services). The company records both short‑term service fees (e.g., shared services with Adovate) and milestone/royalty obligations under long‑running licenses.
  • Spend profile: modest operating spend with targeted pockets of higher cost. Adial reports low to mid six‑figure annual spend lines on shared services and third‑party fees, while future manufacturing and late‑stage trial costs will push spend higher as Phase 3 progresses.
  • Regulatory and timeline sensitivity: high. Clinical progress and third‑party compliance are principal drivers of value; third‑party failures—manufacturers or CROs—directly affect trial timelines and commercial readiness, as the company acknowledges in its risk language.

These characteristics create a classic small‑cap biotech operating model: asset‑centric, capital‑intensive at late stages, vendor‑dependent for execution.

Material constraints and what they imply for partner risk

Company disclosures surface several constraints that shape supplier risk and contract strategy:

  • Adial is a licensee of core IP from the University of Virginia under an exclusive, worldwide license with associated annual minimum royalties and milestone payments — this is a material, long‑dated obligation and a foundation of the business model.
  • The firm employs short‑term consulting contracts (e.g., a nine‑month master services agreement with The Keswick Group) for partnering and business development, indicating tactical outsourcing for BD activities.
  • Several relationships are classified as service providers in filings (sales agents, shared services, CROs, cloud providers), signaling routine outsourcing across capital markets, operations, and trial execution.
  • Reported spend bands in filings place recurring vendor payments in sub‑$100k to the $100k–$1m range historically, but future manufacturing and Phase 3 work will materially increase vendor spend.
  • The company explicitly calls third‑party contractors and manufacturers out as potential sources of delay; regulatory compliance of vendors is therefore a primary operational risk.

These constraints should be read as company‑level signals about contract strategy, vendor dependence, and where operational failure would have the largest impact.

Investment implications and risk framing

  • Upside depends on clinical execution and commercialization readiness. The addition of Thermo Fisher and Cambrex strengthens manufacturing credibility and supports an eventual commercial pathway; Cytel and Genomind investments improve trial design and precision‑medicine positioning.
  • Counterparty risk is meaningful. Execution remains dependent on vendors’ regulatory performance and delivery schedules. Investors should track contractual exclusivity, supply lead times, and any CMO change notices.
  • Capital sensitivity is high. With no product revenue and negative EBITDA, Adial will remain reliant on capital markets and transactions such as warrant inducements and ATM programs to fund development; the engagement of A.G.P. and prior ATM arrangements signals ongoing financing activity.

If you want ongoing monitoring of ADIL partner events, supplier risk scoring, and alerts tied to regulatory milestones, learn more at https://nullexposure.com/.

Bottom line and next steps for analysts

Adial has constructed a credible external ecosystem for late‑stage development: two well‑known U.S. manufacturers, a clinical design partner, and a precision testing collaborator, complemented by typical capital markets and IR service providers. The company’s value remains concentrated in clinical success and in sustaining reliable supplier performance through Phase 3 and beyond. For active investors, the priority monitoring items are manufacturing supply agreements, trial start/enrollment metrics, and milestone payments tied to the UVA license.

For tailored supplier diligence, partner scoring, or tracker feeds for ADIL and peer biotechs, visit https://nullexposure.com/ and sign up for the supplier intelligence package.